Mutations of glucocorticoid receptor differentially affect AF2 domain activity in a steroid-selective manner to alter the potency and efficacy of gene induction and repression

Biochemistry

Volumn 47, Issue 29, 2008, Pages 7648-7662

  Tao, Yong Guang ^a   Xu, Yong ^b   Xu, H Eric ^b   Simons Jr , S Stoney ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONES;

GENE INDUCTION; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR (GR-LBD); STEROID HORMONES; TRANSCRIPTIONAL ACTIVITIES;

DIGITAL INTEGRATED CIRCUITS;

AF2 PROTEIN; DEACYLCORTIVAZOL; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HORMONE RECEPTOR STIMULATING AGENT; NUCLEAR RECEPTOR COACTIVATOR 2; STEROID;

ANIMAL CELL; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; GENE EXPRESSION; GENE INDUCTION; GENE MUTATION; GENE REPRESSION; HUMAN; HUMAN CELL; LIGAND BINDING; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; STRUCTURE ACTIVITY RELATION; X RAY ANALYSIS;

ANIMALS; BLOTTING, WESTERN; CELL LINE; CERCOPITHECUS AETHIOPS; COS CELLS; DEXAMETHASONE; GENE EXPRESSION; HUMANS; MUTAGENESIS, SITE-DIRECTED; NUCLEAR RECEPTOR COACTIVATOR 2; POINT MUTATION; PREGNATRIENES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, GLUCOCORTICOID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEROIDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 47649127453     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi800472w     Document Type: Article

References (63)

1. Williams, S. P., and Sigler, P. B. (1998) Atomic structure of progesterone complexed with its receptor. Nature 393, 392-396.
2. Bledsoe, R. K., Montana, V. G., Stanley, T. B., Delves, C. J., Apolito, C. J., McKee, D. D., Consler, T. G., Parks, D. J., Stewart, E. L., Willson, T. M., Lambert, M. H., Moore, J. T., Pearce, K. H., and Xu, H. E. (2002) Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110, 93-105.
3. Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engstrom, O., Ohman, L., Greene, G. L., Gustafsson, J.-A., and Carlquist, M. (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389, 753-758.
4. Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., and Greene, G. L. (1998) The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95, 927-937.
5. Kauppi, B., Jakob, C., Farnegardh, M., Yang, J., Ahola, H., Alarcon, M., Calles, K., Engstrom, O., Harlan, J., Muchmore, S., Ramqvist, A. K., Thorell, S., Ohman, L., Greer, J., Gustafsson, J. A., Carlstedt-Duke, J., and Carlquist, M. (2003) The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J. Biol. Chem. 278, 22748-22754.
6. Samuels, H. H., and Tomkins, G. M. (1970) Relation of steroid structure to enzyme induction in hepatoma tissue culture cells. J. Mol. Biol. 52, 57-74.
7. Rousseau, G. G., and Schmit, J.-P. (1977) Structure-activity relationships for glucocorticoids. Determination of receptor binding and biological activity. J. Steroid Biochem. 8, 911-919.
8. Simons, S. S., Thompson, E. B., and Johnson, D. F. (1979) Anti-inflammatory pyrazolo-steroids: Potent glucocorticoids containing bulky A-ring substituents and no C3-carbonyl. Biochem. Biophys. Res. Commun. 86, 793-800.
9. Harmon, J. M., Schmidt, T. J., and Thompson, E. B. (1981) Deacylcortivazol acts through glucocorticoid receptors. J. Steroid Biochem. 14, 273-279.
10. Webster, J. C., and Cidlowski, J. A. (1999) Mechanisms of glucocorticoid-receptor-mediated repression of gene expression. Trends Endocrinol. Metab. 10, 396-402.
11. Jakacka, M., Ito, M., Weiss, J., Chien, P. Y., Gehm, B. D., and Jameson, J. L. (2001) Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. J. Biol. Chem. 276, 13615-13621.
12. Rogatsky, I., Trowbridge, J. M., and Garabedian, M. J. (1997) Glucocorticoid receptor-mediated cell cycle arrest is achieved through distinct cell-specific transcriptional regulatory mechanisms. Mol. Cell. Biol. 17, 3181-3193.
13. Schena, M., Freedman, L. P., and Yamamoto, K. R. (1989) Mutations in the glucocorticoid receptor zinc finger region that distinguish interdigitated DNA binding and transcriptional enhancement activities. Genes Dev. 3, 1590-1601.
14. Reichardt, H. M., Kaestner, K. H., Tuckermann, J., Kretz, O., Wessely, O., Bock, R., Gass, P., Schmid, W., Herrlich, P., Angel, P., and Schutz, G. (1998) DNA binding of the glucocorticoid receptor is not essential for survival. Cell 93, 531-541.
15. Rogatsky, I., Hittelman, A. B., Pearce, D., and Garabedian, M. J. (1999) Distinct glucocorticoid receptor transcriptional regulatory surfaces mediate the cytotoxic and cytostatic effects of glucocorticoids. Mol. Cell. Biol. 19, 5036-5049.
16. Liu, W., Hillmann, A., and Harmon, J. (1995) Hormone-independent repression of AP-1-inducible collagenase promoter activity by glucocorticoid receptors. Mol. Cell. Biol. 15, 1005-1013.
17. deLange, P., Koper, J. W., Huizenga, N. A. T. M., Brinkmann, A. O., deJong, F. H., Karl, M., Chrousos, G. P., and Lamberts, S. W. J. (1997) Differential hormone-dependent transcriptional activation and repression by naturally occurring human glucocorticoid receptor variants. Mol. Endocrinol. 11, 1156-1164.
18. Ray, D. W., Suen, C.-S., Brass, A., Soden, J., and White, A. (1999) Structure/function of the human glucocorticoid receptor: Tyrosine 735 is important for transactivation. Mol. Endocrinol. 13, 1855-1863.
19. Suino-Powell, K., Xu, Y., Zhang, C., Tao, Y. G., Tolbert, W. D., Simons, S. S. J., Jr., and Xu, H. E. (2008) Doubling the size of the glucocorticoid receptor ligand binding pocket by deacylcortivazol. Mol. Cell. Biol. 28, 1915-1923.
20. Simons, S. S., Jr. (1994) Function/activity of specific amino acids in glucocorticoid receptors. Vitam. Horm. (San Diego, CA, U.S.) 48, 49-130.
21. Simons, S. S. (1998) Structure and function of the steroid and nuclear receptor ligand-binding domain. In The molecular biology of steroid and nuclear hormone receptors (Freedman, L. P., Ed.) pp 35-104.
22. Simons, S. S., Jr., Pons, M., and Johnson, D. F. (1980) α-Keto mesylate: A reactive thiol-specific functional group. J. Org. Chem. 45, 3084-3088.
23. He, Y., Szapary, D., and Simons, S. S., Jr. (2002) Modulation of induction properties of glucocorticoid receptor-agonist and -antagonist complexes by coactivators involves binding to receptors but is independent of ability of coactivators to augment transactivation. J. Biol. Chem. 277, 49256-49266.
24. Kaul, S., Blackford, J. A., Jr., Chen, J., Ogryzko, V. V., and Simons, S. S., Jr. (2000) Properties of the glucocorticoid modulatory element binding proteins GMEB-1 and -2: Potential new modifiers of glucocorticoid receptor transactivation and members of the family of KDWK proteins. Mol. Endocrinol. 14, 1010-1027.
25. Kaul, S., Blackford, J. A., Jr., Cho, S., and Simons, S. S., Jr. (2002) Ubc9 is a novel modulator of the induction properties of glucocorticoid receptors. J. Biol. Chem. 277, 12541-12549.
26. Wang, Q., Blackford, J. A., Jr., Song, L.-N., Huang, Y., and Simons, S. S., Jr. (2004) Equilibrium interactions of corepressors and coactivators modulate the properties of agonist and antagonist complexes of glucocorticoid receptors. Mol. Endocrinol. 18, 1376-1395.
27. He, Y., and Simons, S. S., Jr. (2007) STAMP: A novel predicted factor assisting TIF2 actions in glucocorticoid receptor-mediated induction and repression. Mol. Cell. Biol. 27, 1467-1485.
28. Giannoukos, G., Silverstein, A. M., Pratt, W. B., and Simons, S. S., Jr. (1999) The seven amino acids (547-553) of rat glucocorticoid receptor required for steroid and hsp90 binding contain a functionally independent LxxLL motif that is critical for steroid binding. J. Biol. Chem. 274, 36527-36536.
29. Rogatsky, I., Zarember, K. A., and Yamamoto, K. R. (2001) Factor recruitment and TIF2/GRIP1 corepressor activity at a collagenase-3 response element that mediates regulation by phorbol esters and hormones. EMBO J. 20, 6071-6083.
30. Simons, S. S., Jr. (2003) The importance of being varied in steroid receptor transactivation. Trends Pharmacol. Sci. 24, 253-259.
31. Simons, S. S., Jr. (2006) How much is enough? Modulation of dose-response curve for steroid receptor-regulated gene expression by changing concentrations of transcription factor. Curr. Top. Med. Chem. 6, 271-285.
32. Sarlis, N. J., Bayly, S. F., Szapary, D., and Simons, S. S., Jr. (1999) Quantity of partial agonist activity for antiglucocorticoids complexed with mutant glucocorticoid receptors is constant in two different transactivation assays but not predictable from steroid structure. J. Steroid Biochem. Mol. Biol. 68, 89-102.
33. Bresnick, E. H., John, S., Berard, D. S., LeFebvre, P., and Hager, G. L. (1990) Glucocorticoid receptor-dependent disruption of a specific nucleosome on the mouse mammary tumor virus promoter is prevented by sodium butyrate. Proc. Natl. Acad. Sci. U.S.A. 87, 3977-3981.
34. Rogatsky, I., Wang, J. C., Derynck, M. K., Nonaka, D. F., Khodabakhsh, D. B., Haqq, C. M., Darimont, B. D., Garabedian, M. J., and Yamamoto, K. R. (2003) Target-specific utilization of transcriptional regulatory surfaces by the glucocorticoid receptor. Proc. Natl. Acad. Sci. U.S.A. 100, 13845-13850.
35. Szapary, D., Huang, Y., and Simons, S. S., Jr. (1999) Opposing effects of corepressor and coactivators in determining the dose-response curve of agonists, and residual agonist activity of antagonists, for glucocorticoid receptor regulated gene expression. Mol. Endocrinol. 13, 2108-2121.
36. Song, L.-N., Huse, B., Rusconi, S., and Simons, S. S., Jr. (2001) Transactivation specificity of glucocorticoid vs. progesterone receptors: Role of functionally different interactions of transcription factors with amino- and carboxyl-terminal receptor domains. J. Biol. Chem. 276, 24806-24816.
37. Cho, S., Kagan, B. L., Blackford, J. A., Jr., Szapary, D., and Simons, S. S., Jr. (2005) Glucocorticoid receptor ligand binding domain is sufficient for the modulation of both the dose-response curve of receptor-agonist complexes and the partial agonist activity of receptor-antisteroid complexes by glucocorticoid receptors, coactivator TIF2, and Ubc9. Mol. Endocrinol. 19, 290-311.
38. Kim, Y., Sun, Y., Chow, C., Pommier, Y. G., and Simons, S. S., Jr. (2006) Effects of acetylation, polymerase phosphorylation, and DNA unwinding in glucocorticoid receptor transactivation. J. Steroid Biochem. Mol. Biol. 100, 3-17.
39. Rogatsky, I., Luecke, H. F., Leitman, D. C., and Yamamoto, K. R. (2002) Alternate surfaces of transcriptional coregulator GRIP1 function in different glucocorticoid receptor activation and repression contexts. Proc. Natl. Acad. Sci. U.S.A. 99, 16701-16706.
40. Heck, S., Kullmann, M., Gast, A., Ponta, H., Rahmsdorf, H. J., Herrlich, P., and Cato, A. C. B. (1994) A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBO J. 13, 4087-4095.
41. Tao, Y., Williams-Skipp, C., and Scheinman, R. I. (2001) Mapping of glucocorticoid receptor DNA binding domain surfaces contributing to transrepression of NF-κB and induction of apoptosis. J. Biol. Chem. 276, 2329-2332.
42. Wang, D., and Simons, S. S., Jr. (2005) Corepressor binding to progesterone and glucocorticoid receptors involves the AF-1 domain and is inhibited by molybdate. Mol. Endocrinol. 19, 1483-1500.
43. Wang, D., Wang, Q., Awasthi, S., and Simons, S. S. (2007) Aminoterminal domain of TIF2 is involved in competing for corepressor binding to glucocorticoid and progesterone receptors. Biochemistry 46, 8036-8049.
44. Huang, Y., and Simons, S. S. (1999) Functional analysis of R651 mutations in the putative helix 6 of rat glucocorticoid receptors. Mol. Cell. Endocrinol. 158, 117-130.
45. Vottero, A., Kino, T., Combe, H., Lecomte, P., and Chrousos, G. P. (2002) A novel, C-terminal dominant negative mutation of the GR causes familial glucocorticoid resistance through abnormal interactions with p160 steroid receptor coactivators. J. Clin. Endocrinol. Metab. 87, 2658-2667.
46. Cho, S., Blackford, J. A., and Simons, S. S., Jr. (2005) Role of activation function domain 1, DNA binding, and coactivator in the expression of partial agonist activity of glucocorticoid receptor complexes. Biochemistry 44, 3547-3561.
47. Clarkson, M. W., Gilmore, S. A., Edgell, M. H., and Lee, A. L. (2006) Dynamic coupling and allosteric behavior in a nonallosteric protein. Biochemistry 45, 7693-7699.
48. Hilser, V. J., and Thompson, E. B. (2007) Intrinsic disorder as a mechanism to optimize allosteric coupling in proteins. Proc. Natl. Acad. Sci. U.S.A. 104, 8311-8315.
49. van Tilborg, M. A. A., Lefstin, J. A., Kruiskamp, M., Teuben, J., Boelens, R., Yamamoto, K. R., and Kaptein, R. (2000) Mutations in the glucocorticoid receptor DNA-binding domain mimic an allosteric effect of DNA. J. Mol. Biol. 301, 947-958.
50. Shiau, A. K., Barstad, D., Radek, J. T., Meyers, M. J., Nettles, K. W., Katzenellenbogen, B. S., Katzenellenbogen, J. A., Agard, D. A., and Greene, G. L. (2002) Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat. Struct. Biol. 9, 359-364.
51. Shulman, A. I., Larson, C., Mangelsdorf, D. J., and Ranganathan, R. (2004) Structural determinants of allosteric ligand activation in RXR heterodimers. Cell 116, 417-429.
52. Zwart, W., Griekspoor, A., Berno, V., Lakeman, K., Jalink, K., Mancini, M., Neefjes, J., and Michalides, R. (2007) PKA-induced resistance to tamoxifen is associated with an altered orientation of ERa towards co-activator SRC-1. EMBO J. 26, 3534-3544.
53. Stevens, A., Garside, H., Berry, A., Waters, C., White, A., and Ray, D. (2003) Dissociation of steroid receptor coactivator 1 and nuclear receptor corepressor recruitment to the human glucocorticoid receptor by modification of the ligand-receptor interface: The role of tyrosine 735. Mol. Endocrinol. 17, 845-859.
54. Pan, Q., Shai, O., Misquitta, C., Zhang, W., Saltzman, A. L., Mohammad, N., Babak, T., Siu, H., Hughes, T. R., Morris, Q. D., Frey, B. J., and Blencowe, B. J. (2004) Revealing global regulatory features of mammalian alternative splicing using a quantitative microarray platform. Mol. Cell 16, 929-941.
55. Ip, J. Y., Tong, A., Pan, Q., Topp, J. D., Blencowe, B. J., and Lynch, K. W. (2007) Global analysis of alternative splicing during T-cell activation. RNA 13, 563-572.
56. Bishop, A. C., Ubersax, J. A., Petsch, D. T., Matheos, D. P., Gray, N. S., Blethrow, J., Shimizu, E., Tsien, J. Z., Schultz, P. G., Rose, M. D., Wood, J. L., Morgan, D. O., and Shokat, K. M. (2000) A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature 407, 395-401.
57. Cohen, M. S., Zhang, C., Shokat, K. M., and Taunton, J. (2005) Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 308, 1318-1321.
58. Heck, S., Bender, K., Kullmann, M., Gottlicher, M., Herrlich, P., and Cato, A. C. B. (1997) IκBα independent downregulation of NF-κB activity by glucocorticoid receptor. EMBO J. 16, 4698-4707.
59. Vayssiere, B. M., Dupont, S., Choquart, A., Petit, F., Garcia, T., Marchandeau, C., Gronemeyer, H., and Resche-Rigon, M. (1997) Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol. Endocrinol. 11, 1245-1255.
60. Ali, A., Thompson, C. F., Balkovec, J. M., Graham, D. W., Hammond, M. L., Quraishi, N., Tata, J. R., Einstein, M., Ge, L., Harris, G., Kelly, T. M., Mazur, P., Pandit, S., Santoro, J., Sitlani, A., Wang, C., Williamson, J., Miller, D. K., Thompson, C. M., Zaller, D. M., Forrest, M. J., Carballo-Jane, E., and Luell, S. (2004) Novel N-arylpyrazolo[3,2-c]-based ligands for the glucocorticoid receptor: Receptor binding and in vivo activity. J. Med. Chem. 47, 2441-2452.
61. Schacke, H., Schottelius, A., Docke, W. D., Strehlke, P., Jaroch, S., Schmees, N., Rehwinkel, H., Hennekes, H., and Asadullah, K. (2004) Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc. Natl. Acad. Sci. U.S.A. 101, 227-232.
62. Wang, J. C., Shah, N., Pantoja, C., Meijsing, S. H., Ho, J. D., Scanlan, T. S., and Yamamoto, K. R. (2006) Novel arylpyrazole compounds selectively modulate glucocorticoid receptor regulatory activity. Genes Dev. 20, 689-699.
63. Kallen, J., Lattmann, R., Beerli, R., Blechschmidt, A., Blommers, M. J., Geiser, M., Ottl, J., Schlaeppi, J. M., Strauss, A., and Fournier, B. (2007) Crystal structure of human estrogen-related receptor α in complex with a synthetic inverse agonist reveals its novel molecular mechanism. J. Biol. Chem. 282, 23231-23239.